<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01815788</url>
  </required_header>
  <id_info>
    <org_study_id>12-PP-17</org_study_id>
    <nct_id>NCT01815788</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid</brief_title>
  <acronym>TEO FIRST</acronym>
  <official_title>Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A personal sound amplifying device (PASP) like Teo First is a wearable electronic product
      that is not intended to compensate for impaired hearing, but rather is intended for
      non-hearing impaired consumers to amplify sounds in the environment for a number of reasons,
      such as for recreational activities. Nevertheless, a lot of mild and moderate impaired
      hearing people don't want to buy and wear all day a real hearing aid.

      The goal of our study is to evaluate the benefit of such a device for mild and moderate
      presbycusis patient 60 years of age and older, with no previous hearing aid.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Audiometric  tests (pure tone and speech) in silence and noise, with and without Teofirst</measure>
    <time_frame>7 to 15 days after the first use of Teofirst</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>audiometric and mental tests</measure>
    <time_frame>D7 to 15 and D 40</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glasgow Hearing Aid Benefit Profile (GHABP)
Acceptability and use questionnaire
ANL (Acceptable Noise Level) test
Mini Mental State Examination
Instrumental Activities of Daily Living (IADL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>- Mild and Moderate Presbycusis (20 to 50 dB Average Hearing Loss at 500, 1000, 2000 Hz and 4000 Hz)</condition>
  <arm_group>
    <arm_group_label>Teo first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000,  2000 Hz and 4000 Hz)
Patient 60 years of age and older,
No previous hearing aid</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of a personal sound amplifying device = TeoFirst</intervention_name>
    <arm_group_label>Teo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Wish to increase hearing

          -  Moral commitment to use the device

          -  Ability to understand the study

          -  Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000,  2000
             Hz and 4000 Hz)

          -  Patient 60 years of age and older,

          -  No previous hearing aid

        Exclusion Criteria:

          -  Inability to use the device

          -  Previous use of a hearing aid

          -  local intolerance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas GUEVARA, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanina OLIVERI, CRA</last_name>
    <phone>04 92 03 42 54</phone>
    <email>oliveri.v@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa ESPIN, CRA stagiaire</last_name>
    <phone>04 92 03 42 54</phone>
    <email>espin.v@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas GUEVARA, PH</last_name>
      <email>guevara.n@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GUEVARA, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvan GAHIDE, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier GUERIN, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume SACCO, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Michel TURPIN, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 20, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Presbycusis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
